World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease
World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease
December 10, 2019
3 min watch
Save

AI tool for NAFLD could ‘make biopsies history’

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LOS ANGELES — In this video exclusive, Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School, chief of endocrinology, diabetes and metabolism at the Boston VA Healthcare System and director of human nutrition at Beth Israel Deaconess Medical Center, discusses a new artificial intelligence and machine learning tool for nonalcoholic fatty liver disease prediction.

According to Mantzoros, the tool was designed to improve the detection and treatment of NAFLD and “make biopsies history.” Mantzoros shared promising results for sensitivity and specificity with the tool, which incorporates metabolomics, lipidomics and other factors to provide diagnoses and prognoses.

Watch the video for more.